sellModerate cluster of 2
Bhatnagar Anish sold $966k of SLNO
CHIEF EXECUTIVE OFFICER at SOLENO THERAPEUTICS INC. 21,091 shares at an average of $45.78, traded Jan 2, 2025, filed Jan 6, 2025.
Warning score
58Value
$966k
21,091 shares
Holdings after
698,462
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$966k at market
- 0Share of holdings soldSold 2.9% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-000953, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2025 | SOpen-market sale Common Stock | -10,077 | $45.37 | $457k | 709,476 | Jan 6, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock | -860 | $45.92 | $39k | 708,616 | Jan 6, 2025 |
| Jan 3, 2025 | SOpen-market sale Common Stock | -10,154 | $46.18 | $469k | 698,462 | Jan 6, 2025 |
Related signals
Other insiders at SOLENO THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | SOLENO THERAPEUTICS INC | Michael F. Huang Sr. VP of Clinical Development | $200k 6,582 shares | -14% | |
| 41Moderate | SOLENO THERAPEUTICS INC | Meredith Manning Chief Commercial Officer | $229k 7,522 shares | -10% | |
| 14Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $317k 3,830 shares | -22% | |
| 0Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $22k 266 shares | -2% | |
| 28Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $265k 3,782 shares | -12% | |
| 70Notable | SOLENO THERAPEUTICS INC | Bhatnagar Anish CHIEF EXECUTIVE OFFICER | $47M 699,095 shares | -93% | |
| 40Moderate | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $11M 156,315 shares | -139% | |
| 50Moderate | SOLENO THERAPEUTICS INC | Michael F. Huang Sr. VP of Clinical Development | $1.0M 14,583 shares | -35% | |
| 34Weak | SOLENO THERAPEUTICS INC | Patricia C Hirano SEE REMARKS | $139k 3,030 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.